@article{523545718d5148749c8a3c8bedbc4416,
title = "Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma",
abstract = "Background: Little is known about real-world outcomes for first-line and anti-PD-1 second-line treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC). Patients & methods: Retrospective data of advanced/metastatic ESCC patients treated between 2011 and 2021 were collected from Flatiron Health. Median duration of therapy (mDoT) and median overall survival (mOS) were evaluated for patients initiating first-line and anti-PD-1 second-line therapy. Results: Among patients receiving first-line therapy (n = 948), mDoT was 1.4 months and mOS was 16.0 months, with mOS of 16.0 and 18.0 months for the non-immunotherapy and immunotherapy cohorts, respectively. Among patients receiving anti-PD-1 second-line therapy (n = 60), mDoT was 5.7 months and mOS was 10.1 months. Conclusion: Patients with advanced/metastatic ESCC have short duration of therapy, and overall survival remains limited. This real-world study underscores the need for efficacious treatments for advanced/metastatic ESCC in the first- and second-line setting. Direct comparisons of emerging therapies in the real world are urgently needed.",
keywords = "advanced/metastatic esophageal squamous cell carcinoma, anti-PD-1 therapy, Flatiron data, immunotherapy, survival, treatment patterns",
author = "Daniel Ahn and Michelle Sidel and Laura Panattoni and Naomi Sacks and Jennifer Hernandez and Reginald Villacorta",
note = "Funding Information: This study was funded by Novartis Pharmaceuticals Corporation, which was involved in study design; in the collection, analysis and interpretation of data; in writing of the report; and in the decision to submit the article for publication. Employees from Novartis Pharmaceuticals Corporation participated as authors in publication, in compliance with authorship guidelines from the International Committee of Medical Journal Editors. All authors contributed to and approved the article. L Panattoni, N Sacks and J Hernandez received funding from Novartis Pharmaceuticals Corporation to conduct this research. R Villacorta and M Sidel were employees of Novartis Pharmaceutical Corporation when this research was conducted. D Ahn has received personal fees from Exelixis, Novartis, Genentech, Eisai, Daiichi Sankyo and Advanced Accelerator Applications. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2022 Novartis Pharmaceuticals.",
year = "2022",
doi = "10.2217/fon-2022-0708",
language = "English (US)",
volume = "18",
pages = "3419--3433",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "30",
}